Product Details
Additional Information
| Product Name | Ilaris 150 Mg/mL Vial |
| Active Ingredient | Canakinumab |
| Mechanism of Action | IL-1ß inhibitor; binds to interleukin-1 beta, preventing inflammatory signaling |
| Dosage Form | Lyophilized Powder for Injection |
| Strength | 150 mg/mL |
| Route of Administration | Subcutaneous (SC) |
| Dosing Frequency | Every 4 to 8 weeks, depending on condition |
| Onset of Action | Gradual reduction in inflammation within days |
| Common Side Effects | Injection site reactions, infections, headache, dizziness |
| Serious Risks | Increased risk of infections, neutropenia, hypersensitivity reactions |
| Precautions | Avoid live vaccines; monitor for signs of infection |
| Monitoring Parameters | CBC, infection markers, liver function tests |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F); protect from light |
| Packaging | Single-dose vial |
| Usage | Treatment of IL-1ß-mediated autoinflammatory diseases |
Description
Ilaris 150 mg/mL vial is a monoclonal antibody formulation containing canakinumab, designed for subcutaneous administration. It is an interleukin-1 beta (IL-1ß) inhibitor used in the treatment of autoinflammatory conditions. By selectively binding to IL-1ß, it prevents inflammatory signaling, reducing symptoms associated with excessive immune activation. The medication is indicated for periodic fever syndromes, including cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
In systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD), Ilaris reduces systemic inflammation, fever, and joint manifestations by suppressing IL-1ß activity. It provides sustained symptom control with a single subcutaneous dose administered every four to eight weeks, depending on the condition.
Ilaris is supplied as a lyophilized powder in a single-use vial requiring reconstitution before administration. It should be prepared using sterile techniques and injected subcutaneously by a healthcare professional. Patients should be monitored for potential hypersensitivity reactions, infections, and neutropenia.
Frequently Asked Questions (FAQs)
The cost of ILARIS 150 MG/ML VIAL is $available for registerd members only
ILARIS 150 MG/ML VIAL is manufactured by Novartis.
You can purchase ILARIS 150 MG/ML VIAL on our website at https://supplies.pipelinemedical.com/product/detail/ilaris-150-mg-ml-vial-424063